Author:
Bi Goue DenisGohore,LI Jun,Nekka Fahima
Abstract
Abstract
Background
Pharmacokinetic and pharmacodynamic (PK/PD) indices are increasingly being used in the microbiological field to assess the efficacy of a dosing regimen. In contrast to methods using MIC, PK/PD-based methods reflect in vivo conditions and are more predictive of efficacy. Unfortunately, they entail the use of one PK-derived value such as AUC or Cmax and may thus lead to biased efficiency information when the variability is large. The aim of the present work was to evaluate the efficacy of a treatment by adjusting classical breakpoint estimation methods to the situation of variable PK profiles.
Methods and results
We propose a logical generalisation of the usual AUC methods by introducing the concept of "efficiency" for a PK profile, which involves the efficacy function as a weight. We formulated these methods for both classes of concentration- and time-dependent antibiotics. Using drug models and in silico approaches, we provide a theoretical basis for characterizing the efficiency of a PK profile under in vivo conditions. We also used the particular case of variable drug intake to assess the effect of the variable PK profiles generated and to analyse the implications for breakpoint estimation.
Conclusion
Compared to traditional methods, our weighted AUC approach gives a more powerful PK/PD link and reveals, through examples, interesting issues about the uniqueness of therapeutic outcome indices and antibiotic resistance problems.
Publisher
Springer Science and Business Media LLC
Subject
Health Informatics,Modeling and Simulation
Reference40 articles.
1. Bryskier A: antibacterials and antifungals. Edited by: André Bryskier. 2005, Washington, D.C: ASM Press
2. Fauchère J-L: Bactériologie générale et médicale/Jean-Louis Fauchère, Jean-Loup Avril. 2002, Paris: Ellipses
3. Robert-Dernuet S: Antibiotiques et antibiogrammes/Sabine Robert-Dernuet; préface de Michel Laverdière; [illustrations, Bertrand Lachance. 1995, Paris: Vigot
4. MacGowan AP, Wise R: Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother. 2001, 48 (Suppl 1): 17-28.
5. Jorgensen JH: Who defines resistance? The clinical and economic impact of antimicrobial susceptibility testing breakpoints. Semin Pediatr Infect Dis. 2004, 15: 105-108. 10.1053/j.spid.2004.01.014.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献